INVESTOR ALERT: Boston Scientific Corporation (BSX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – RGRD Law

Core Viewpoint - Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market competition [1][3]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [2]. Allegations of the Lawsuit - The lawsuit claims that during the class period, Boston Scientific executives made false statements about the company's revenue projections and growth potential, downplaying risks from market competition and macroeconomic factors [3]. - It is alleged that Boston Scientific's goal to grow its share in the electrophysiology market at twice the market rate was not met due to new competitors affecting its market share [3]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing: - Q4 2025 GAAP net income of $672 million ($0.45 per share), up from $566 million ($0.38 per share) a year prior, with adjusted EPS of $0.80 compared to $0.70 [4]. - Full year 2025 GAAP net income of $2.898 billion ($1.94 per share), compared to $1.853 billion ($1.25 per share) the previous year, with adjusted EPS of $3.06 versus $2.51 [4]. - The reported Q4 EPS of $0.45 fell short of the company's guidance range of $0.48 to $0.52, leading to a stock price drop of over 17% [4]. Legal Process - Investors who purchased Boston Scientific stock during the class period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of all class members [5]. - The lead plaintiff can choose a law firm to litigate the case, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [6].